Oramed

ORMP NASDAQ
3.580
0.000
0.00%
Opening 09:30 06/20 EDT
Open
3.580
Prev Close
3.580
High
3.580
Low
3.580
Volume
365
Avg Vol (3M)
75.75K
52 Week High
7.84
52 Week Low
2.780
% Turnover
0.00%
Market Cap
62.22M
1D
5D
1M
3M
1Y
5Y

Company Profile

Oramed Pharmaceuticals Inc. (Oramed) is engaged in the field of oral delivery solutions for drugs and vaccines presently delivered via injection. Oramed’s flagship product, an orally ingestible insulin capsule in phase II clinical trials, is focused on the treatment of diabetes. The Company is developing orally ingestible protein oral delivery (POD) technology for the delivery of drugs presently administered by way of injection. Oramed’s delivery platform protects protein sand enhances their absorption, allowing them to reach the blood stream through the portal vein. The Company’s products include ORMD-0801, Oral insulin capsule; ORMD 0901, Oral Exenatide capsule; and combination therapy of ORMD 0801 + ORMD 0901. ORMD-0801 is under phase II A clinical trials. ORMD-0901 is under preclinical/Investigational New Drug (IND) stage under phase I B.
MORE >

Recently

Name
Price
%Change